McKesson (MCK, $127.16) To Move Headquarters From California to Texas
McKesson Corp. will be shifting its headquarters from San Francisco to Las Colinas, Texas. The move will be effective April1. The company, which distributes pharmaceutical products and provides healthcare technology, said that it will move 500 employees from San Francisco to elsewhere around the country and would retain 1,400 jobs in California.
“We are excited to strengthen our presence in Texas and make Las Colinas our official global headquarters,” said John Hammergren, CEO of McKesson, in a statement. “Making this move will improve efficiency, collaboration and cost-competitiveness, while providing an exceptional work environment for our employees.” (as reported by San Francisco Chronicle).
McKesson generated revenue of $198 billion last year, the sixth highest among U.S. public companies.
Aroon Indicator for MCK shows an upward move is likely
MCK's Aroon Indicator triggered a bullish signal on November 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 319 similar instances where the Aroon Indicator showed a similar pattern. In of the 319 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 21, 2025. You may want to consider a long position or call options on MCK as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in of 384 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MCK moved out of overbought territory on November 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator moved out of overbought territory. In of the 50 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for MCK turned negative on November 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MCK broke above its upper Bollinger Band on November 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.377). P/E Ratio (27.799) is within average values for comparable stocks, (31.037). Projected Growth (PEG Ratio) (1.217) is also within normal values, averaging (2.635). Dividend Yield (0.003) settles around the average of (0.029) among similar stocks. P/S Ratio (0.288) is also within normal values, averaging (141.703).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors
Advertisement